Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Study Conducted by Dr. Vince Clinical ResearchKANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a...
Disability
Dick and Betsy DeVos Family Foundation, SoldierStrong Donate Robotic Exoskeleton, Virtual Reality Treatment System to Help Vets Take Next Step Forward
ORLANDO, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- The Dick and Betsy DeVos Family Foundation and SoldierStrong today announced donations...
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from...
Study Finds Majority of Kentuckians Favor Universal Healthcare
LOUISVILLE, Ky., Oct. 24, 2022 (GLOBE NEWSWIRE) -- An overwhelming majority of Kentuckians favor a national government health plan, according...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY,...
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations,...
VitalHub Corp. Announces Acquisition of Community Data Solutions
TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSX: VHI) (the “Company” or “VitalHub”) is pleased to announce today...
Bass Pro and CorVel Named Risk Management Team of the Year by Business Insurance
US Insurance Award Recognizes Their Innovative Solution for Managing Return-to-Work and Temporary Total DisabilityFORT WORTH, Texas, Oct. 11, 2022 (GLOBE...
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST),...
ReWalk Takes Another Step Toward Medicare Coverage
ReWalk to submit first cases for Medicare coverage through Medicare Administrative Contractors (MACs)Centers for Medicare and Medicaid Services (CMS) affirms...
AmMax Bio Provides Update on AMB-05X Program for Tenosynovial Giant Cell Tumor (TGCT)
New Patents Issued and Fast Track Designation Support Development of the Only Locally-Administered Drug Treatment for TGCT Positive Proof-of-Concept Results...
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis MoonLake announces...
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
Results highlight a potential novel treatment for diabetic and other retinopathiesUnique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth...
GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization...
Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine
WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million...
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
German Federal Social Court Schedules Hearing on Classification of Exoskeleton Medical Devices for Spinal Cord Injured Individuals
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk"...